Aprepitant for prevention of nausea and vomiting secondary to high-dose Cyclophosphamide administered to patients undergoing Autologous Peripheral Blood Stem Cells mobilization: A Phase II Trial

Lignende værker

• A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
  af: Abidi, Muneer H., et al.
  Udgivet: (2012)
• Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide
  af: Atallah, Ehab, et al.
  Udgivet: (2010)
• Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
  af: Abidi, Muneer H., et al.
  Udgivet: (2012)
• Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma
  af: Bhutani, Divaya, et al.
  Udgivet: (2013)
• Chemotherapy-Induced Nausea and Vomiting #285
  af: Tageja, Nishant, et al.
  Udgivet: (2014)